Lung cancer is one of the most common malignancies and tumor-related causes of death
worldwide. In the last years, significant advances have been observed in the treatment of non
small cell lung cancer, in particular for the population of patients with a driver genetic
mutation like EGFR and ALK. For the remaining cases, the main novelty has been represented by
immunotherapy with anti-PD1/PDL1 agents, which have proved a benefit over previous standard
of care (platinum-based chemotherapy in first line and docetaxel in second line). , Only
patients wih tumors expressing high PD-L1 levels have had access to immunotherapy alone as
first line treatment. For all the remaining cases, the standard-of-care treatment in the
first-line setting has remained platinum-based chemotherapy for several years. This algorithm
has been recently changed by the approval of combined chemotherapy(platinum salt +
pemetrexed) and immunotherapy (pembrolizumab) as a first-line therapy for patients with lung
adenocarcinoma and low/absent PD-L1 expression. This regimen has entered into clinical
practice following the positive results of a clinical trial, showing superior outcome with
the combination than with chemotherapy alone. Lung adenocarcinoma with LKB1 mutations or
macro/micro deletions has a particularly aggressive behavior and seems to be resistant to the
effects of immunotherapy, either alone or in combination with chemotherapy. Indeed, such a
population appears to be disadvantaged as regards therapeutic options and requires the
development of different approaches. LKB1 enzyme is involved in intracellular pathways that
are crucial in the regulation of cancer cell metabolism. Metabolic reprogramming is a key
step in tumorigenesis and several metabolic pathways, including glucose uptake and
utilization, or lipid biosynthesis and utilization, are deregulated in cancer cells compared
to their normal counterpart. Cells with hypo-active or inactive LKB1 are peculiar in that
they show an exquisite vulnerability to energetic deprivation. Indeed, they are unable to
survive when exposed to nutrient deprivation or drugs that affect cancer cell bioenergetics
or specific metabolic processes. In particular, the class of drugs known as biguanides, which
include the antidiabetic compound metformin, are able to inhibit mitochondrial metabolism and
to reduce the intracellular concentration of ATP, and have shown antitumor activity in mouse
xenografts of LKB1-mutated lung adenocarcinomas. Based on the well known effects of metformin
on cancer cell metabolism, as well as on preclinical evidence showing synergistic activity of
cisplatin and metformin in lung cancer cell lines and animal models with LKB1 deletion, we
hypothesize that combining chemoimmunotherapy (platinum salt + pemetrexed + pembrolizumab)
with either metformin (MERCY arm), or metformin plus a lowcalorie, low-carbohydrate,
low-protein diet also known as Fasting Mimicking Diet (FMD) (FAME arm), may improve the
efficacy of standard treatment alone for patients with LKB1-inactive lung adenocarcinoma.
The patients considered eligible and enrolled in the study will be included in FAME, MERCY or
BORN arms according to the aforementioned eligibility criteria. Patients in each arm will
receive the following treatment:
- FAME -> up to a maximum of 4 cycles of a platinum salt + pemetrexed + pembrolizumab in
association to metformin and to tri-weekly, 5 day-long cycles of FMD.
- MERCY -> up to a maximum of 4 cycles of a platinum salt + pemetrexed + pembrolizumab in
association to metformin.
- BORN -> standard treatment at investigator's choice or observation only in case of
clinical conditions contraindicating any active therapy.
In both arms FAME and MERCY, the patients with stable or responding disease after 4 cycles of
chemotherapy will continue with maintenance pemetrexed and pembrolizumab in association to
metformin until disease progression and/or inacceptable toxicity.
FAME arm (chemo-immunotherapy + metformin + FMD):
Inclusion criteria:
1. Age included between 18 and 75 years.
2. Histologically confirmed diagnosis of LKB1-inactive lung adenocarcinoma, as defined on
the basis of absence of LKB1 expression at immunoistochemistry, and/or presence of
pathogenic LKB1 mutations/deletions at next-generation sequencing analysis.
3. Absence of EGFR mutations, ALK and ROS-1 rearrangements, and absence of high
expression of PD-L1 (≥ 50% in immunohistochemistry).
4. Advanced disease, defined as unresectable, locally advanced (stage IIIB) or metastatic
(stage IV) lung adenocarcinoma, which is not candidate to be treated with concomitant
or sequential definitive chemo-radiation.
5. Signed and dated informed consent, indicating that the patient has been informed on
all the aspects of the study prior to the enrollment.
6. Patient's will able to respect the protocol recommendations about the FMD regimen, as
well as about laboratory tests and other procedures.
7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
8. In case of presence of brain metastases, the patient can be candidated to be enrolled
in the study, provided that neurologic symptoms are absent, the patient does not need
radiotherapy or treatment with steroids at a dose ≥ 4 mg per day of dexamethasone or
analogues.
9. Adequate bone marrow and organ function, defined as follows:
- absolute neutrophil count ≥ 1.5 x 103/L;
- platelet count ≥ 100 x 103/L;
- hemoglobin ≥ 9.0 g/dL;
- serum albumin-corrected calcium within normal range or with anomalies graded ≤ 1
according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
if not clinically significant;
- potassium within normal range or corrected with supplements;
- glomerular filtration rate (GFR) > 60 mL/min, estimated on a 24-hour urine exam
and calculated from serum creatinine with Cockroft-Gault formula;
- uric acid < 10 mg/dL;
- AST and ALT ≤ 2.5 times upper normal limits, or ≤ 5 times upper normal limits in
case of liver metastases;
- serum bilirubin < 1.5 times upper normal limits, except for patients with Gilbert
syndrome who will be considered amenable to be enrolled if total bilirubin is <
3.0 times upper normal limits or direct bilirubin is < 1.5 times upper normal
limits;
- serum albumin > 3 g/dL.
10. Fasting plasma glucose concentration ≤ 200 mg/dL.
11. For women of childbearing potential, consent to maintain abstinence from sexual
intercourse or to use highly effective contraceptive methods (that is, with a failure
rate < 1% per year) for the whole duration of the study and for almost 30 days after
the conclusion of the FMD. Abstinence is acceptable only if in line with the patient's
lifestyle. Adequate contraceptive methods include tube ligation, male sterilization,
hormone implants, injectable or oral hormone contraceptives and some intra-uterine
devices. Alternatively, two different contraceptive methods must be combined (e.g. two
barrier methods like condom and cervical cap) in order to obtain a failure rate <1%
per year. Barrier methods must always be associated to a sperm killer.
Exclusion criteria:
1. Previous systemic therapies for advanced lung cancer.
2. Evidence of disease relapse within 6 months from the conclusion of adjuvant or
neoadjuvant platinum-based chemotherapy.
3. Diagnosis of other malignancies in the previous 5 years, except for adequately treated
basal or squamous skin cancer or radically excised cervical cancers. Other
malignancies diagnosed more than 5 years before the diagnosis of lung cancer must have
been radically treated without evidence of relapse at the time of patient enrollment.
4. Body mass index (BMI) < 20 kg/m2.
5. Anamnesis of alcohol abuse.
6. Non-intentional weight loss ≥ 5% in the previous 3 months, unless the patient has a
BMI > 25 kg/ m2 at the time of enrollment in the study, or non-intentional weight loss
of ≥ 10% in the previous 3 months, unless the patients has a BMI > 22 kg/m2 at the
time of the enrollment in the study. In both cases, weight must have remained stable
for at least one month.
7. Active pregnancy or breast feeding.
8. Active B or C hepatitis.
9. Serious infection in the previous 4 weeks before the start of FMD, including, but not
limited to, potential hospitalizations for complications of infections, bacteriemia or
serious pneumonitis.
10. Active autoimmune diseases requiring systemic treatments (e.g. systemic steroids or
immune suppressants).
11. Recent diagnosis of hypothyroidism requiring systemic substitutive hormonal therapy
and without stabilization of hormonal profile (fT3, fT4 and TSH within the normal
range).
12. Diagnosis of type 1 or 2 diabetes mellitus requiring pharmacologic therapy (including,
but not limited to, insulin, secretagogues and metformin).
13. Serious impairment of gastrointestinal function or gastrointestinal disease
potentially altering nutrient digestion or absorption during re-alimentation phase
(e.g. active gastric or intestinal ulcerative disease, uncontrolled nausea, vomiting,
diarrhea, malabsorption syndrome, small intestine resection).
14. Anamnesis of human immunodeficiency virus (HIV).
15. Anamnesis of clinically significant heart disease including:
1. angina pectoris, coronary bypass, symptomatic pericarditis, myocardial infarction
in the previous 12 months from the beginning of experimental therapy;
2. congestive heart failure (NYHA III-IV).
16. Anamnesis of cardiac arrhythmias (e.g. ventricular tachycardia, chronic atrial
fibrillation, complete bundle branch block, high grade atrio-ventricular block like
bi-fascicular block, type II Mobitz and third grade atrio-ventricular block, nodal
arrhythmias, supra-ventricular arrhythmias) or conduction abnormalities in the
previous 12 months from the beginning of experimental therapy.
17. Reduction in left ventricular ejection fraction to < 50% at the cardiac scan with
radionuclides or at echocardiography.
18. Previous episodes of symptomatic hypotension leading to loss of consciousness.
19. Plasma fasting glucose ≤ 65 mg/dL.
20. Active therapy with systemic steroids at a dose ≥ 25 mg per day of prednisone or
equivalent for any reason.
21. Medical or psychiatric comorbidities rendering the patient not candidate to the
clinical trial, according to the investigator's judgement.
22. pO2 < 60 mmHg, lactates above normal limits and pH value below normal limits at
arterial hemogasanalysis.
23. Need for chronic oxygen therapy.
24. Other cardiac, liver, lung or renal comorbidities, not specified in the previous
inclusion or exclusion criteria, but potentially exposing the patient to a high risk
of lactic acidosis.
MERCY arm (chemo-immunotherapy + metformin):
Inclusion criteria:
1. Age ≥18 years.
2. Histologically confirmed diagnosis of LKB1-inactive lung adenocarcinoma, as defined on
the basis of absence of LKB1 expression at immunoistochemistry, and/or presence of
pathogenic LKB1 mutations/deletions at next-generation sequencing analysis.
3. Absence of EGFR mutations, ALK and ROS-1 rearrangements, and absence of high
expression of PD-L1 (≥ 50% in immunohistochemistry).
4. Advanced disease, defined as unresectable, locally advanced (stage IIIB) or metastatic
(stage IV) lung adenocarcinoma, which is not candidate to be treated with concomitant
or sequential definitive chemo-radiation.
5. Signed and dated informed consent, indicating that the patient has been informed on
all the aspects of the study prior to the enrollment.
6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
7. Adequate bone marrow and organ function, defined as follows:
- absolute neutrophil count ≥ 1.5 x 103/L;
- platelet count ≥ 100 x 103/L;- hemoglobin ≥ 9.0 g/dL;
- serum albumin-corrected calcium within normal range or with anomalies graded ≤ 1
according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
if not clinically significant;
- potassium within normal range or corrected with supplements;
- glomerular filtration rate (GFR) > 60 mL/min, estimated on a 24-hour urine exam
and calculated from serum creatinine with Cockroft-Gault formula;
- uric acid < 10 mg/dL;
- AST and ALT ≤ 2.5 times upper normal limits, or ≤ 5 times upper normal limits in
case of liver metastases;
- serum bilirubin < 1.5 times upper normal limits, except for patients with Gilbert
syndrome who will be considered amenable to be enrolled if total bilirubin is <
3.0 times upper normal limits or direct bilirubin is < 1.5 times upper normal
limits;
- serum albumin > 3 g/dL.
8. For women of childbearing potential, consent to maintain abstinence from sexual
intercourse or to use highly effective contraceptive methods (that is, with a failure
rate < 1% per year) for the whole duration of the study and for almost 30 days after
the conclusion of the metformin treatment. Abstinence is acceptable only if in line
with the patient's lifestyle. Adequate contraceptive methods include tube ligation,
male sterilization, hormone implants, injectable or oral hormone contraceptives and
some intra-uterine devices. Alternatively, two different contraceptive methods must be
combined (e.g. two barrier methods like condom and cervical cap) in order to obtain a
failure rate <1% per year. Barrier methods must always be associated to a sperm
killer.
Exclusion criteria:
1. Previous systemic therapies for advanced lung cancer.
2. Evidence of disease relapse within 6 months from the conclusion of adjuvant or
neoadjuvant platinum-based chemotherapy.
3. Diagnosis of other malignancies in the previous 5 years, except for adequately treated
basal or squamous skin cancer or radically excised cervical cancers. Other
malignancies diagnosed more than 5 years before the diagnosis of lung cancer must have
been radically treated without evidence of relapse.
4. Anamnesis of alcohol abuse.
5. Active pregnancy or breast feeding.
6. Active B or C hepatitis.
7. Serious infection in the previous 4 weeks before the start of metformin treatment,
including, but not limited to, potential hospitalizations for complications of
infections, bacteriemia or serious pneumonitis.
8. Active autoimmune diseases requiring systemic treatments (e.g. systemic steroids or
immune suppressants).
9. Recent diagnosis of hypothyroidism requiring systemic substitutive hormonal therapy
and without stabilization of hormonal profile (fT3, fT4 and TSH within the normal
range).
10. Diagnosis of type 1 or 2 diabetes mellitus requiring pharmacologic therapy (including,
but not limited to, insulin, secretagogues and metformin).
11. Serious impairment of gastrointestinal function or gastrointestinal disease
potentially altering nutrient digestion or absorption during re-alimentation phase
(e.g. active gastric or intestinal ulcerative disease, uncontrolled nausea, vomiting,
diarrhea, malabsorption syndrome, small intestine resection).
12. Anamnesis of human immunodeficiency virus (HIV).
13. Anamnesis of clinically significant heart disease including:
1. angina pectoris, coronary bypass, symptomatic pericarditis, myocardial infarction
in the previous 12 months from the beginning of experimental therapy;
2. congestive heart failure (NYHA III-IV).
14. Anamnesis of cardiac arrhythmias (e.g. ventricular tachycardia, chronic atrial
fibrillation, complete bundle branch block, high grade atrio-ventricular block like
bi-fascicular block, type II Mobitz and third grade atrio-ventricular block, nodal
arrhythmias, supra-ventricular arrhythmias) or conduction abnormalities in the
previous 12 months from the beginning of experimental therapy.
15. Reduction in left ventricular ejection fraction to < 50% at the cardiac scan with
radionuclides or at echocardiography.
16. Medical or psychiatric comorbidities rendering the patient not candidate to the
clinical trial, according to the investigator's judgement.
17. pO2 < 60 mmHg, lactates above normal limits and pH value below normal limits at
arterial hemogasanalysis.
18. Need for chronic oxygen therapy.
19. Other cardiac, liver, lung or renal comorbidities, not specified in the previous
inclusion or exclusion criteria, but potentially exposing the patient to a high risk
of lactic acidosis.
BORN (observational arm):
Inclusion criteria:
1. Age ≥18 years.
2. Histologically confirmed diagnosis of LKB1-inactive lung adenocarcinoma, as defined on
the basis of absence of LKB1 expression at immunoistochemistry, and/or presence of
pathogenic LKB1 mutation at next-generation sequencing analysis.
3. Absence of EGFR mutations, ALK and ROS-1 rearrangements, and absence of high
expression of PD-L1 (≥ 50% in immunohistochemistry).
4. Advanced disease, defined as unresectable, locally advanced (stage IIIB) or metastatic
(stage IV) lung adenocarcinoma, which is not candidate to be treated with concomitant
or sequential definitive chemo-radiation.
5. Signed and dated informed consent, indicating that the patient has been informed on
all the aspects of the study prior to the enrollment.
6. At least one exclusion criteria of FAME and MERCY arm.
Exclusion criteria:
None
Patients who are eligible for the FAME arm will be preferentially proposed to be enrolled
in the FAME. If they refuse, then they will be proposed to be enrolled in the MERCY arm. If
they also refuse to be enrolled in the MERCY arm, they will be proposed to be enrolled in
the BORN arm.
Patients who are eligible for the MERCY arm will be preferentially proposed to be enrolled
in the MERCY arm; if they refuse, the will be proposed to be enrolled in the BORN arm.
Finally, patients who are ineligible for both the FAME and MERCY arms will be proposed to
be enrolled in the BORN arm.
